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ABSTRACT 
An economical, precise, rapid and accurate RP HPLC method has been developed for the simultaneous estimation of Olmesartan Medoxomil and 
Cilnidipine in bulk and tablet dosage form. Separation was carried out on Jasco HPLC system equipped with HiQ sil C18 column (250 × 4.6 mm i.d.) 
and PDA detector using Methanol: 40 mM Potassium dihydrogen ortho phosphate buffer (90:10 v/v) as the mobile phase.Ortho-phosphoric acid 
was used to adjust pH to 3.0, and detection was carried out at 254 nm. Results were linear in the range of 5-30 μg/ml for Cilnidipine and 10-50 
μg/ml for Olmesartan Medoxomil respectively. The method was successfully applied for the analysis of drugs in pharmaceutical formulation. Results 
of the analysis were validated statistically and by recovery studies. 
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INTRODUCTION 
Cilnidipine (CILNI) chemically, 1,4-Dihydro- 2,6-dimethyl-4-(3-
nitrophenyl)-3,5-pyridinecarboxylic acid 2-methoxyethyl(2E)-3-
phenyl-propenyl ester is a dual blocker of L-type voltage-gated 
calcium channels in vascular smooth muscle and N-type calcium 
channels in sympathetic nerve terminals[1]. Olmesartan Medoxomil 
(OLME) chemically, 2,3-dihydroxy-2-butenyl-(1-hydroxy-1-methyl 
ethyl)-2-propyl-1-[P-(O-1H-tetrazole-5-ylphenyl)benzyl] imidazole-
5- carboxylate, cyclic 2,3-carbonate. Olmesartan Medoxomil is a 
prodrug, which after ingestion liberates the only active metabolite, 
Olmesartan. Olmesartan is a competitive and selective angiotensin 2 
receptor antagonist. Both drugs used in combination to treat 
hypertension [1]. Literature survey reveals that cilnidipine can be 
estimated by spectrophotometric [2, 3, 4], reverse phase high-
performance liquid chromatography (RP-HPLC) [5, 6] and high 
performance thin layer chromatography (HPTLC) [7.8] methods 
either as a single or in combination with other drugs in 
pharmaceutical preparations. Analytical methods reported for OLME 
includes spectrophotometric [9, 10], HPLC [11, 12, 13], and HPTLC 
[14, 15] either as a single drug or in combination with other drugs. 
Literature survey reveals that not a single HPLC method of analysis 
has yet been reported for simultaneous analysis of CILNI and OLME. 
The objective of the present investigations was to develop a rapid, 
accurate, economical and validated reverse-phase high-performance 
liquid chromatographic (RP-HPLC) method for the simultaneous 
estimation so that can play important role in quantification of CILNI 
and OLME in bulk and tablet dosage form The proposed method is 
optimized and validated as per the International Conference on 
Harmonization (ICH) guidelines [16]. 
MATERIALS AND METHODS 
Chemicals and Reagents 
Pharmaceutical grade working standards of CILNI were obtained as 
gift sample from J. B. Chemicals and Pharmaceuticals Ltd. (Daman) 
and OLME from Macleods Pharmaceutical Ltd. (Mumbai) used as 
such without further purification. The pharmaceutical dosage form 
used in this study was Nexvas-o tablets (Macleods Pharmaceutical 
Ltd., Mumbai, India), labeled to contain 10 mg of CILNI and 20 mg of 
OLME procured from the local market. Methanol (HPLC grade), 
Potassium dihydrogen orthophosphate (AR grade), Ortho 
phosphoric acid (AR grade) purchased from Thomas Baker 
(chemical) Pvt. Ltd. (Mumbai) and double distilled water was used 
for analysis. 
Instrumentation and Chromatographic conditions 
Jasco HPLC system consisting of Jasco PU-2089 plus HPLC pump 
with Jasco MD-2018 plus PDA detector and ChromNAV software was 
used for analysis. Separation was carried out on HiQ sil C18 (250 x 4.6 
mm i.d.) column using mobile phase methanol: 40mM potassium 
dihydrogen orthophosphate buffer (90:10 v/v) and pH adjusted to 3.0 by 
orthophosphoric acid at flow rate of 1 ml/ min. 20 μl Samples were 
injected using syringe and detection was carried out at 254 nm. 
Preparation of standard stock solutions 
Standard stock solution of CILNI and OLME was prepared separately 
by dissolving 10 mg of drug in 10 ml methanol to get concentration 
of 1000 μg /ml from which 1 ml of solution was further diluted to 10 
ml with mobile phase to get a working standard solution having 
concentration 100 μg /ml for both the drugs. 
Procedure for analysis of tablet formulation 
Twenty tablets were weighed accurately and powdered. A quantity 
of tablet powder equivalent to 10 mg of CILNI and 20mg of OLME 
was weighed and transferred to100 ml volumetric flask containing 
about 80 ml of methanol and sonicated for 20 min and volume was 
made up to the mark with the methanol.  
The solution was filtered through Whatman paper No. 41. 
Further dilution are done with the mobile phase to get solution 
of concentration 10μg/ ml for OLME and 5 μg/ ml for CILNI After 
setting the chromatographic conditions and stabilizing the 
instrument, the tablet sample solution was injected, 
chromatogram was obtained and the peak areas were recorded. 
The injections were repeated six times and the amount of each 
drug present per tablet was estimated from the respective 
calibration curves. 
System Suitability 
The system suitability was assessed by six replicate injections of the 
mixture containing 5μg/ ml and 10 μg/ ml of CILNI and OLME 
respectively. The resolution, peak asymmetry, number of theoretical 
plates, and tailing factor were calculated as represented in Table 2. 
Method Validation 
The method was validated for linearity, accuracy and intra-day and 
inter-day precision and robustness, in accordance with ICH 
guidelines. [16] 
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The stock solution of OLME and CILNI was prepared by dissolving 
10mg of both drugs in 10 ml methanol separately to obtain a 
concentration of 1000µg/ml. From this stock solution further 
dilutions were made in mobile phase to obtain concentrations of 5-
30μg/ml and 10-50μg/ml for CILNI and OLME respectively. 
 A graph was plotted as concentration of drugs versus peak area 
response it was found to be linear for both the analytes. (Shown in 
Figure 2) From the standard stock solution, a mixed standard 
solution was prepared containing 10μg/ml of OLME and 5μg/ml of 
CILNI. The system suitability test was performed on six replicate 
injections of mixed standard solution. 
 
Table 1: It shows analysis data of nexvas-o tablet formulation with statistical evaluation 
Amt of Drug Present (mg) Amt of Drug Found (mg ) %Amount estimated* %RSD 
CILNI OLME CILNI OLME CILNI OLME CILNI OLME 
10 20 9.96 20.22 99.89 101.15 0.3040 1.53 
*Average of six determinations 
 
Table 2: It shows system suitability parameters for RP-HPLC method 
Parameter CILNI OLME 
Retention time (min.) 6.32 2.47 
Theoretical Plates 4723 2823 
Resolution  12.23 
Tailing factor 1.66 0.90 
 
The obtained values describe the suitability of the system for the 
analysis of these drugs in combination. Mean retention time was 
found to be 2.47 for OLME and 6.32 for CILNI respectively. The 
representative chromatogram of the standard solution of mixture is 
shown in Figure 1. 
 
 
Fig. 1: It shows representative chromatogram obtained for 
standard mixture of OLME (10 μg/ml, 2.47 min) and CILNI (5 
μg/ml, 6.32 min) 
 
 
Fig. 3: It shows calibration curve for CILNI and OLME 
 
Precision 
One set of three different concentrations of mixed standard 
solutions of OLME and CILNI were prepared. All the solutions were 
analyzed thrice, in order to record interday and intraday variations 
in the results. For Inter day variations study three different 
concentrations of the mixed standard solutions in linearity range 
were analyzed on three consecutive days. The peak areas were 
recorded and relative standard deviation (RSD) was calculated for 
both series of analysis. 
Table 3: It shows precision studies for CILNI and OLME 
Drug Drug content % Std. Dev. %RSD* SE 
 Inter-Day Precision 
CILNI 99.70 0.408 0.409 0.16 
OLME 99.66 0.334 0.335 0.13 
 Intra-Day Precision 
CILNI 98.11 0.809 0.825 0.33 
OLME 99.06 0.214 0.216 0.028 
* Average of three determinations; RSD relative standard deviation: SE standard error 
 
Accuracy 
To check the accuracy of the method recovery studies were carried 
out by addition of standard drug solution to pre-analyzed sample 
solution at three different levels 80%, 100% and 120%. The 
percentages of recoveries were calculated,  
the results of which are represented in Table 4. 
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Table 4: Recovery studies of OLME and CILNI 
DRUG Amount of drug taken* (µg/ml) Amount of drug added* 
(µg/ml) 
Amount of drug found* 
(µg/ml) 
%amount of drug recoverd * %RSD 
CILNI 10 08 17.9092 99.49 0.3993 
 10 10 19.7133 98.56 0.7331 
 10 12 21.7642 98.92 0.8523 
OLME 20 16 36.1499 100.41 0.7422 
 20 20 39.8944 99.73 0.6259 
 20 24 44.0034 100.00 0.4693 
* Average of three determinations; RSD relative standard deviation 
 
Limit of detection and Limit of quantitation 
Limit of detection and Limit of quantitation were calculated as 3.3 σ 
/S and 10 σ /S respectively; where σ is the standard deviation of the 
response (y-intercept) and S is the slope of the calibration plot. 
Robustness 
In the robustness study, the influence of small, deliberate variations of 
the analytical parameters on retention time of the drugs was examined. 
The following three factors were selected for change: flow rate of the 
mobile phase (1 ± 0.1 ml /min), pH of mobile phase (3 ± 0.1) and 
concentration of buffer (10 ± 1ml). It was observed that there were no 
marked changes in the chromatograms, which demonstrated that the 
RP-HPLC method developed is robust. 
RESULTS AND DISCUSSION 
Results were found to be linear in the concentration range of 10-50 
μg /ml for OLME and 5-30 μg /ml for CILNI with r2 
 
= 0.999 
respectively. The proposed method was also evaluated by the assay 
of commercially available tablets containing OLME and CILNI. The % 
assay was found to be 99.79 % for CILNI and 101.15% for OLME.The 
% recovery was found to be in the range of 98.56 to 99.49 for CILNI 
and 99.73 to 100.41 for OLME. The method was found to be accurate 
and precise, as indicated by recovery studies and % RSD not more 
than 2. Robustness of the method checked after deliberate 
alterations of the analytical parameters shown no marked changes 
in the chromatograms (RSD NMT 2%), which demonstrated that the 
RP-HPLC method developed is robust. The summary of validation 
parameters of proposed HPLC method is given in Table 5. 
Table 5: It shows summary of validation parameters of proposed RP-HPLC method 
Parameter CILNI OLME 
Linearity range (ng/ spot) 100-200 200-400 
Correlation co-efficient 0.995 0.996 
Slope (m) 13.41 4.140 
Intercept (c) 726.0 584.8 
Precision (intraday) %RSD 1.44 1.28 
Precision (interday) %RSD 1.71 1.59 
Accuracy 98.61 to 100.87 98.48 to 99.51 
LOD (μg /ml) 2.00 2.24 
LOQ (μg /ml) 6.009 6.69 
 
CONCLUSION 
The developed and validated RP-HPLC method is found to be rapid, 
accurate, precise and robust, thus can be used for routine analysis of 
olmesartan medoxomil and cilnidipine in combined tablet dosage 
form. 
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